With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
BIL also holds an option to increase its equity stake by an additional 15%
The CSR initiative will offer Digital Radiology X-Ray service to Dholera and 33 surrounding villages in the region
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
Ultra-high purity surfactant for biologics and parenteral drug formulations
Relonchem receives marketing authorization for Moxonidine tablets
Subscribe To Our Newsletter & Stay Updated
